Trial Profile
A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of Surface Antigen, Inactivated, Adjuvanted With MF59C.1 Influenza Vaccine, Formulation 2009-2010, When Administered to Elderly Subjects.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Influenza virus vaccine (Primary) ; MF 59
- Indications Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Novartis
- 19 Aug 2009 New trial record